Arcturus Therapeutics COO Sells $610,573 Worth of Stock

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Free Report) made headlines recently when its Chief Operating Officer, Pad Chivukula, sold 17,435 shares of the company’s stock. The transaction took place on Monday, March 25th, with the stock being sold at an average price of $35.02, resulting in a total transaction of $610,573.70. Chivukula now holds 473,448 shares in the company, valued at $16,580,148.96. This information was disclosed in a filing with the Securities and Exchange Commission.

This is not the first time Chivukula has made a significant trade. On Tuesday, March 19th, he sold 8,565 shares of Arcturus Therapeutics stock at an average price of $35.01. The total transaction for this sale amounted to $299,860.65.

In terms of stock performance, Arcturus Therapeutics opened at $33.77 on Friday. Over the past year, the stock has traded between a low of $17.52 and a high of $43.81. The company currently has a market capitalization of $909.09 million, with a negative P/E ratio of -32.47. Its beta stands at 2.64. The stock’s fifty-day moving average is $36.19, while its two-hundred-day moving average is $29.39.

Several Wall Street analysts have shared their thoughts on Arcturus Therapeutics. Canaccord Genuity Group initiated coverage on the stock and assigned it a “buy” rating, along with a price target of $90.00. William Blair also expressed optimism with their “outperform” rating. HC Wainwright gave a “buy” rating and set a price target of $60.00. Citigroup raised their price target from $40.00 to $48.00, also giving the company a “buy” rating. Overall, the consensus rating for Arcturus Therapeutics is “Moderate Buy,” with an average target price of $57.71.

Institutional investors have been active in trading Arcturus Therapeutics shares. Price T Rowe Associates Inc. MD increased its holdings by 2.3% in the fourth quarter, acquiring an additional 360 shares. SummerHaven Investment Management LLC also boosted its holdings by 1.7% in the fourth quarter, buying an extra 378 shares. Formidable Asset Management LLC increased its holdings by 3.3%, while Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its holdings by 5.9%. Great West Life Assurance Co. Can saw a significant increase of 29.9% in their holdings. Overall, 94.54% of the stock is owned by hedge funds and other institutional investors.

Arcturus Therapeutics Holdings Inc is a late-stage clinical messenger RNA medicines and vaccine company. Their focus is on the development of infectious disease vaccines and products related to liver and respiratory rare diseases. The company utilizes LUNAR lipid-mediated delivery and STARR mRNA technology platforms.

For more information on Arcturus Therapeutics and its recent activities, interested readers can refer to their latest research report.

Follow AsumeTech on

More From Category

More Stories Today

Leave a Reply